HER2/neu protein expression and fine needle breast aspiration from Argentinean patients with non-palpable breast lesions

Domínguez,Wendy Gabriela; Nardi,Héctor; Montero,Héctor; Vincent,Esteban; Corte,María Marta; Balogh,Gabriela Andrea

doi:10.3892/etm_00000094

HER2/neu protein expression and fine needle breast aspiration from Argentinean patients with non-palpable breast lesions

Authors:
- Wendy Gabriela Domínguez
- Héctor Nardi
- Héctor Montero
- Esteban Vincent
- María Marta Corte
- Gabriela Andrea Balogh
View Affiliations

Affiliations: Department of Biochemistry and Genetics, Texas A&M University, College Station, TX, USA
Published online on: July 1, 2010 https://doi.org/10.3892/etm_00000094
Pages: 597-602

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The objective of this pilot project was to investigate whether the breast fine needle aspiration (FNA) technique is a useful tool for determining the increased risk of breast cancer in patients with non-palpable breast lesions. FNA is a minimally invasive technique that isolates mammary epithelial cells from breast cells in the suspicious region. In this study, two FNA samples were collected from 12 patients. The level of HER2/neu expression at the mRNA level (in serum) was measured in each patient. As gene amplification is characteristic of cancer cells and may assist in diagnosis and prognostic assessment, it is crucial that gene amplification of HER2/neu in patients with non-palpable breast lesions is compared to breast biopsy results. In serum, the level of HER2/neu was determined by ELISA assay. Gene amplification was determined by PCR and confirmed by IHC employing monoclonal ERRB2 in the FNA sample. The results indicate that FNA has a good correlation with breast biopsy. FNA combined with mammographic imaging is a strong tool for determining favorable treatment options for patients.

View Figures

View References

1.	Spivey GH, Perry BW, Clark VA, et al: Predicting the risk of cancer at the time of breast biopsy. Variation in the benign to malignant ratio. Am Surg. 48:326–332. 1982.PubMed/NCBI
2.	Molloy M, Azarow K, Garcia VF, et al: Enhanced detection of preinvasive breast cancer: combined role of mammography and needle localization biopsy. J Surg Oncol. 40:152–154. 1989. View Article : Google Scholar : PubMed/NCBI
3.	Basset LW, Liu TH, Giuliano AE, et al: The prevalence of carcinoma in palpable vs. impalpable, mammographically detected lesions. AJR Am J Rowntgenol. 157:21–24. 1991. View Article : Google Scholar : PubMed/NCBI
4.	Sickles E: Screening for breast cancer with mammography. Radiology. 179:463–468. 1991.
5.	Lidbrink E, Elfving J, Fussell J, et al: Neglected aspects of false positive findings of mammography in breast cancer screening: analysis of false positive cases from the Stockholm trial. BMJ. 312:273–276. 1996. View Article : Google Scholar : PubMed/NCBI
6.	Burrell HC, Pinder SE, Wilson AR, et al: The positive predictive value of mammographic signs: a review of 425 non-palpable breast lesions. Clin Radiol. 51:277–281. 1996. View Article : Google Scholar : PubMed/NCBI
7.	Wrensch MR, Petrakis NL, King EB, et al: Breast cancer incidence in women with abnormal cytology in nipple aspirates of breast fluid. Am J Epidemiol. 135:130–141. 1992.PubMed/NCBI
8.	Wrensch MR, Petrakis NL, Miike R, et al: Breast cancer risk in women with abnormal cytology in nipple aspirates of breast fluid. J Natl Cancer Inst. 93:1791–1798. 2001. View Article : Google Scholar : PubMed/NCBI
9.	Fabian CJ, Kimler BF, Zalles CM, et al: Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model. J Natl Cancer Inst. 92:1217–1227. 2000. View Article : Google Scholar
10.	Wright T and McGechan A: Breast cancer: new technologies for risk assessment and diagnosis. Mol Diagn. 7:49–55. 2003.PubMed/NCBI
11.	Dooley WC, Ljung BM, Veronesi U, et al: Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. J Natl Cancer Inst. 93:1624–1632. 2001. View Article : Google Scholar : PubMed/NCBI
12.	Petrakis NL: Nipple aspirate fluid in epidemiologic studies of breast disease. Epidemiol Rev. 15:188–195. 1993.PubMed/NCBI
13.	Wrensch M, Petrakis NL, King EB, et al: Breast cancer risk associated with abnormal cytology in nipple aspirates of breast fluid and prior history of breast biopsy. Am J Epidemiol. 137:829–833. 1993.PubMed/NCBI
14.	Alitalo K and Schwab M: Oncogene amplification in tumor cells. Adv Cancer Res. 47:235–281. 1986. View Article : Google Scholar
15.	Schwab M and Amler LC: Amplification of cellular oncogenes: a predictor of clinical outcome in human cancer. Genes Chromosomes Cancer. 1:181–193. 1990. View Article : Google Scholar : PubMed/NCBI
16.	Einarsdóttir K, Rosenberg LU, Humphreys K, et al: Comprehensive analysis of the ATM, CHEK2 and ERBB2 genes in relation to breast tumour characteristics and survival: a population-based case-control and follow-up study. Breast Cancer Res. 8:R672006.PubMed/NCBI
17.	Choi YH, Ahn JH, Kim SB, et al: Tissue microarray-based study of patients with lymph node-negative breast cancer shows that HER2/neu overexpression is an important predictive marker of poor prognosis. Ann Oncol. 20:1337–1343. 2009. View Article : Google Scholar : PubMed/NCBI
18.	Egervari K, Toth J, Nemes Z, et al: An alternative and reliable real-time quantitative PCR method to determine HER2/neu amplification in breast cancer. Appl Immunohistochem Mol Morphol. 17:247–254. 2009. View Article : Google Scholar : PubMed/NCBI
19.	D’Alessandro C, Dellapasqua S, Orlando L, et al: Role of endocrine responsiveness and HER2/neu overexpression in inflammatory breast cancer treated with multimodality preoperative therapy. Breast J. 14:435–441. 2008.PubMed/NCBI
20.	Dunn L and Demichele A: Genomic predictors of outcome and treatment response in breast cancer. Mol Diagn Ther. 13:73–90. 2009. View Article : Google Scholar : PubMed/NCBI
21.	Motomura K, Koyama H, Noguchi S, et al: Detection of c-erbB-2 gene amplification in nipple discharge by means of polymerase chain reaction. Breast Cancer Res. 33:89–92. 1995. View Article : Google Scholar : PubMed/NCBI